From: Clinical applications of PD-L1 bioassays for cancer immunotherapy
Agent | Nivolumab | Pembrolizumab | Atezolizumab | Durvalumab |
---|---|---|---|---|
Antibody | 28-8 | 22C3 | SP142 | SP263 |
Isotype and host species | Rabbit IgG | Mouse IgG | Rabbit IgG | Rabbit IgG |
Binding site | Extracellular | Extracellular | Intracellular | Intracellular |
Cell scored | Tumor cell | Tumor cell | Tumor cell | Tumor cell |
Tumor stroma | Immune cell | |||
Cutoffs | 1, 5, or ≥10% | ≥50% tumor cell | 1, 5, or ≥10% | ≥25% |
≥1% stroma |